Patent protection. Canadian drug firms boost R&D spending.
作者信息
Spurgeon D
出版信息
Nature. 1992 Feb 20;355(6362):666. doi: 10.1038/355665b0.
DOI:10.1038/355665b0
PMID:1741046
Abstract
摘要
相似文献
1
Patent protection. Canadian drug firms boost R&D spending.
Nature. 1992 Feb 20;355(6362):666. doi: 10.1038/355665b0.
2
3
Patent law. Boost for Canadian drug research.专利法。对加拿大药物研究的推动。
Nature. 1986;322(6076):201. doi: 10.1038/322201a0.
4
Ownership of knowledge--the role of patents in pharmaceutical R&D.知识所有权——专利在制药研发中的作用。
Bull World Health Organ. 2004 Oct;82(10):784-7; discussion 787-90.
5
[From the molecule to the drug: innovation or distribution].
Union Med Can. 1993 Jan-Feb;122(1):4.
6
Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.药品专利与一些国际贸易问题：加拿大、美国与北美自由贸易协定
Clin Ther. 1993 Nov-Dec;15(6):1177-84; discussion 1120.
7
Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney.药物研发中的专利问题：一位药学科学家兼律师的观点
AAPS J. 2005 Oct 27;7(3):E723-8. doi: 10.1208/aapsj070372.
8
Canadian High Court upholds Glaxo Wellcome AZT patent.加拿大高等法院维持葛兰素威康公司齐多夫定的专利。
AIDS Policy Law. 2002 Dec 20;17(22):3.
9
Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.卫生政策还是知识产权政策？关于C-91法案的争论。加拿大医疗保健协会。
Int J Health Care Qual Assur Inc Leadersh Health Serv. 1997;10(2-3):vii-x.
10
Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry.
J Health Econ. 1985 Mar;4(1):43-61. doi: 10.1016/0167-6296(85)90023-2.
Zotero 插件